Bridgeway Capital Management LLC Purchases Shares of 110,140 AbbVie Inc. $ABBV

Bridgeway Capital Management LLC acquired a new stake in AbbVie Inc. (NYSE:ABBV) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 110,140 shares of the company’s stock, valued at approximately $20,444,000.

A number of other institutional investors and hedge funds have also made changes to their positions in ABBV. Conning Inc. raised its holdings in AbbVie by 7.1% during the second quarter. Conning Inc. now owns 191,023 shares of the company’s stock worth $35,458,000 after purchasing an additional 12,690 shares in the last quarter. Dohj LLC boosted its holdings in shares of AbbVie by 41.8% in the 2nd quarter. Dohj LLC now owns 4,529 shares of the company’s stock valued at $802,000 after buying an additional 1,335 shares in the last quarter. First Hawaiian Bank grew its position in shares of AbbVie by 0.8% in the 2nd quarter. First Hawaiian Bank now owns 7,556 shares of the company’s stock valued at $1,403,000 after buying an additional 60 shares during the last quarter. BankPlus Trust Department raised its stake in AbbVie by 3.3% during the 2nd quarter. BankPlus Trust Department now owns 27,113 shares of the company’s stock worth $5,033,000 after acquiring an additional 855 shares in the last quarter. Finally, Whittier Trust Co. lifted its position in AbbVie by 4.0% in the second quarter. Whittier Trust Co. now owns 237,030 shares of the company’s stock valued at $43,997,000 after acquiring an additional 9,073 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Trading Down 0.2%

Shares of ABBV stock opened at $223.45 on Friday. The business’s 50 day moving average is $227.25 and its two-hundred day moving average is $209.59. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The company has a market capitalization of $394.92 billion, a P/E ratio of 169.28, a price-to-earnings-growth ratio of 1.21 and a beta of 0.36. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the prior year, the business earned $3.00 earnings per share. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. AbbVie’s dividend payout ratio (DPR) is 496.97%.

Analysts Set New Price Targets

Several equities analysts have issued reports on ABBV shares. Bank of America raised their price objective on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. BMO Capital Markets raised their price target on AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a research note on Friday, September 12th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. Berenberg Bank raised AbbVie from a “hold” rating to a “buy” rating and increased their price objective for the company from $170.00 to $270.00 in a report on Wednesday, September 17th. Finally, Guggenheim raised their target price on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research report on Monday, October 20th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $244.55.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.